Lee Schwartzberg, MD, FACP | Authors

Integration of Genomic Testing into NCCN Guidelines

July 12, 2021

Dr. Lee Schwartzberg highlights recent changes to the NCCN guidelines in terms of guidance for genomic testing in HR-positive breast cancer based on updates to the RxPONDER trial and data supporting the use of the Breast Cancer Index.

Role of Genomic Testing in HR Positive Breast Cancer

July 07, 2021

Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.